

AVI BIOPHARMA INC  
Form 8-K  
March 11, 2004

## FORM 8-K

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 9, 2004**

## AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

**Oregon**  
(State or other jurisdiction of  
incorporation or organization)

**0-22613**  
(Commission  
File Number)

**93-0797222**  
(IRS Employer  
Identification Number)

**One S.W. Columbia, Suite 1105**  
**Portland, OR 97258**  
(Address of principal executive offices)

**(503) 227-0554**  
Registrant's telephone number, including area code

**Not Applicable**

(Formal name and address, if changed from last report)



**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

Exhibits

99.1. Press release dated March 9, 2004 announcing financial results for the quarter and year ended December 31, 2003.

**Item 12. Results of Operations and Financial Condition.**

On March 9, 2004, AVI BioPharma, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2003. The press release is attached to this Form 8-Ka as Exhibit 99.1.

\* \* \*

*Note:* The information contained in this report on Form 8-K (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on March 11, 2004

AVI BioPharma, Inc.

By: /s/ ALAN P. TIMMINS  
Alan P. Timmins  
*President and Chief Operating Officer*  
*(Principal Operating Officer)*

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Document Description</b>
99.1	Press release dated March 9, 2004 issued by AVI BioPharma, Inc.